Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesMedical Treatment of Pulmonary Arterial Hypertension
Seminars in Respiratory and Critical Care Medicine, 07/29/09
Adamali H et al. – Treatment algorithms have now become more complex, with therapeutic options defined by pulmonary artery vasoreactivity, functional class, and response to treatment. Combination therapies are increasingly considered as clinical trials demonstrating the efficacy of this approach are emerging. Monitoring and measuring the response to treatment in clinical trials and clinical practice are evolving from the historical dependence on functional class and 6–minute walk test to include estimates of the delay in the time to clinical worsening and the response of emerging biomarkers. KEYWORDS
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
The Use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn
American Journal of Perinatology, 10/28/09
Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: A prospective, observational cohort study
Chest, 11/03/09
Pulmonary embolism in pregnancy
The Lancet - Early Online Publication, 11/03/09
Sponsor
Article Search
Sponsor